

**November Webinar organized by the NACP Nuclear
Medicine Physics Committee**

**Radioiodine treatments across the
Nordics – dosimetry and radiation
protection**

Date: 11 Nov 2026 | Time: 13:00 -14:30 CET | Online Event

Link to registration:

<https://events.teams.microsoft.com/event/e26cea86-efcc-4d49-be8c-7fddd2e95389@8b5d4c16-4b46-4cfe-bfa8-0876fc31a035?source=copyLinkLegacyShareLinkDialog>



Helena Lizana



Tommi Noponen



Lars Tore Gyland Mikalsen

Helena Lizana is a medical physics expert at the University Hospital of Umeå, Sweden. She is the modality leader for radionuclide therapies at the Nuclear Medicine Department and has led a group responsible for a radioiodine survey in Sweden. Her PhD thesis from 2007 included dosimetry and tumour control probability in radionuclide therapy.

Tommi Noponen is a medical physics expert at Turku University Hospital, Finland. He is the medical physicist responsible for radioiodine therapies at their department and has also contributed to the Finnish national guidelines regarding good practices in radioiodine therapies.

Lars Tore Gyland Mikalsen is a medical physics expert at Oslo University Hospital, Norway. He has been the medical physicist responsible for radioiodine dosimetry, treatment and radiation protection for the past 13 years. The hospital has performed dosimetry based personalized treatment with activity adjustment for selected high risk cancer patients throughout this period.

Program

Radioiodine therapy has been an essential component of nuclear medicine for many decades, offering an effective and minimally invasive treatment option for both benign and malignant thyroid diseases. While the Nordic countries share many similarities in healthcare organization and treatment philosophy, differences remain regarding dosimetry, administered activities, patient management, and radiation protection practices. These variations provide valuable opportunities for comparison and knowledge exchange. This seminar will provide an overview of radioiodine treatment strategies in the Nordic countries, both for thyrotoxicosis and cancer. By sharing our experiences, we hope that we will find opportunities for continued improvement and collaboration.

1. Sweden: Dosimetry and radiation protection, including results from a national survey (Helena Lizana)
2. Finland: Radioiodine treatments and radiation protection in Finland, including national guideline (Tommi Noponen)
3. Norway: Radioiodine treatments and radiation protection in Norway, including personalized dosimetry-based activity selection in selected cancer patients (Lars Tore Gyland Mikalsen)
4. Open discussion (all)